<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00318513</url>
  </required_header>
  <id_info>
    <org_study_id>AVF3251s</org_study_id>
    <nct_id>NCT00318513</nct_id>
  </id_info>
  <brief_title>Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema</brief_title>
  <official_title>Phase I Study Evaluating the Safety of Bevacizumab in Women With a History of Breast Cancer Suffering From Moderate to Severe Upper Extremity Lymphedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Premiere Oncology of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Premiere Oncology of Arizona</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and side effects of bevacizumab in
      subjects with lymphedema who will initially receive bevacizumab alone and then in combination
      with standard manual lymphatic drainage (MLD) and combined decongestive therapy (CDT). This
      study will help to determine the dose of bevacizumab to be used in future studies of subjects
      with lymphedema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphedema occurs with varying frequency in patients with cancer but approximately 10-15% of
      all breast cancer patients will develop lymphedema following breast cancer treatment.
      Lymphedema in breast cancer patients following axillary lymph node dissection is caused by
      the interruption of the axillary lymphatic system by surgery or radiation therapy, which
      causes an accumulation of fluid in the subcutaneous tissue of the arm, with decreased
      distensibility of tissue around the joints and increased weight of the extremity. The primary
      current therapy employed involves complete decongestive therapy (CDT) which encompasses the
      use of manual lymphatic drainage (MLD) and compression bandaging (CB) to the affected limb.

      The specific contribution of the vascular system to the development of lymphedema is unclear.
      Vascular permeability is a complex process which is primarily controlled by the interaction
      of the ligand vascular endothelial growth factor (VEGF). As a result of the understanding of
      the biology of VEGF and the anecdotal appreciation of women with lymphedema who have noted
      improvement in their lymphedema while on VEGF inhibitor therapy, it is hypothesized that the
      reduction in vascular permeability resulting from the use of a VEGF inhibitor either alone or
      in conjunction with standard decongestive lymphedema therapy may significantly improve the
      outcome for patients with this post-operative complication.

      Bevacizumab is a recombinant humanized monoclonal antibody directed against VEGF. Bevacizumab
      blocks the development of new blood vessels in cancer and it is approved by the FDA for the
      treatment of colon cancer in combination with chemotherapy. While bevacizumab has been
      administered to thousands of patients with cancer, there is only limited information about
      the use of bevacizumab in subjects without active cancer.

      This study will evaluate the safety profile of escalating doses of bevacizumab administered
      intravenously alone for 4 weeks followed by 4 weeks of therapy in combination with manual
      lymph drainage (MLD) and compression bandaging (CB) to patients with moderate to severe
      unilateral upper extremity lymphedema due to prior breast cancer therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>35</enrollment>
  <condition>Lymphedema</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with a history of breast cancer status post (s/p) prior surgical resection
             (i.e., either lumpectomy and radiation, modified radical mastectomy or radical
             mastectomy) with lymphedema defined as a difference in limb volume of at least 500 ml
             by perometric assessment

          -  Lymphedema may be newly diagnosed or previously treated as long as it is Stage I
             (pitting) or II (fibrosis) at the time of study entry.

          -  No known evidence of recurrent or active metastatic breast cancer

          -  No prior chemotherapy within 6 months of study entry and has recovered to grade 1 or
             less from the toxicity of all prior chemotherapy or radiation therapy (with the
             exception of alopecia); ongoing anti-estrogen therapy for post-menopausal survivors is
             permissible.

          -  Normal end organ function defined as: serum creatinine &lt; 1.5 mg/dl or a calculated
             creatinine clearance &gt; 50 ml/min; SGOT and SGPT &lt; 2.5 X upper limit of normal (ULN);
             total bilirubin &lt; 1.5 X ULN; absolute neutrophil count (ANC) &gt; 1,500 cells/µl;
             hemoglobin &gt; 10 g/dl (without transfusions); platelet count &gt; 100,000/µl; serum
             albumin within normal limits (WNL).

        Exclusion Criteria:

          -  Stage III (lymphostatic elephantiasis) lymphedema

          -  Clinical evidence of bilateral lymphedema. Those patients who have undergone bilateral
             breast cancer surgery or prophylactic mastectomy on the non-cancerous breast will be
             excluded.

          -  Any prior history of deep venous thrombosis (DVT) or pulmonary embolus (with the
             exception of prior line-related thrombotic events) or myocardial infarction (MI),
             cerebrovascular accident (CVA) or any other arterial thromboembolic event (i.e.,
             transient ischemic attack [TIA], reversible ischemic neurologic deficit [RIND],
             history of angina pectoris, clinically significant peripheral vascular disease with
             claudication, etc.)

          -  Patients with problems with wound healing (e.g., diabetic ulcers), gastrointestinal
             fistula

          -  Patients receiving therapeutic anti-coagulation including full dose aspirin or
             non-steroidal anti-inflammatory agents known to inhibit platelet function (low dose
             coumadin for port prophylaxis and low dose aspirin are allowed)

          -  Untreated hypertension with a baseline systolic blood pressure (SBP) of &gt; 150 mmHg or
             a diastolic blood pressure (DBP) &gt;100 mmHg will be excluded (stable treated
             hypertension with values less than those noted will be eligible).

          -  A history of infectious complications of the involved arm or those with any
             contraindication to MLD + CB [e.g., congestive heart failure (CHF), DVT, acute or
             chronic renal failure] will be excluded.

          -  Women with a history of CHF [New York Heart Association (NYHA) Class II or greater]
             will be excluded.

          -  Pregnant or breast-feeding

          -  Unwilling to use an appropriate form of barrier contraception for the duration of the
             study and for three months following the last dose of bevacizumab

          -  Those patients who are actively undergoing MLD and/or CB at the time of study entry
             and for up to 4 weeks prior to entry

          -  Unable to provide written informed consent or to comply with study procedures

          -  Baseline urine protein : creatinine ratio &gt; 1.0

          -  Known evidence of a bleeding diathesis or coagulopathy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael S Gordon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Premiere Oncology of Arizona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael S Gordon, MD</last_name>
    <phone>480-860-5000</phone>
    <email>mgordon@premiereoncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Premiere Oncology of Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael S Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Velanovich V, Szymanski W. Quality of life of breast cancer patients with lymphedema. Am J Surg. 1999 Mar;177(3):184-7; discussion 188.</citation>
    <PMID>10219851</PMID>
  </reference>
  <reference>
    <citation>Yeoh EK, Denham JW, Davies SA, Spittle MF. Primary breast cancer. Complications of axillary management. Acta Radiol Oncol. 1986 Mar-Apr;25(2):105-8.</citation>
    <PMID>3012953</PMID>
  </reference>
  <reference>
    <citation>Brennan MJ, DePompolo RW, Garden FH. Focused review: postmastectomy lymphedema. Arch Phys Med Rehabil. 1996 Mar;77(3 Suppl):S74-80. Review.</citation>
    <PMID>8599548</PMID>
  </reference>
  <reference>
    <citation>Kobayashi MR, Miller TA. Lymphedema. Clin Plast Surg. 1987 Apr;14(2):303-13. Review.</citation>
    <PMID>3555946</PMID>
  </reference>
  <reference>
    <citation>Mortimer PS. The pathophysiology of lymphedema. Cancer. 1998 Dec 15;83(12 Suppl American):2798-802. Review.</citation>
    <PMID>9874400</PMID>
  </reference>
  <reference>
    <citation>Bates DO, Levick JR, Mortimer PS. Starling pressures in the human arm and their alteration in postmastectomy oedema. J Physiol. 1994 Jun 1;477(Pt 2):355-63.</citation>
    <PMID>7932226</PMID>
  </reference>
  <reference>
    <citation>Svensson WE, Mortimer PS, Tohno E, Cosgrove DO. Increased arterial inflow demonstrated by Doppler ultrasound in arm swelling following breast cancer treatment. Eur J Cancer. 1994;30A(5):661-4.</citation>
    <PMID>8080683</PMID>
  </reference>
  <reference>
    <citation>Stanton AW, Holroyd B, Northfield JW, Levick JR, Mortimer PS. Forearm blood flow measured by venous occlusion plethysmography in healthy subjects and in women with postmastectomy oedema. Vasc Med. 1998;3(1):3-8.</citation>
    <PMID>9666525</PMID>
  </reference>
  <reference>
    <citation>Mellor RH, Stanton AW, Menadue L, Levick JR, Mortimer PS. Evidence for dermal angiogenesis in breast cancer related lymphedema demonstrated using dual-site fluorescence angiography. Microcirculation. 2002 Jul;9(3):207-19.</citation>
    <PMID>12080418</PMID>
  </reference>
  <reference>
    <citation>Roberts CC, Stanton AW, Pullen J, Bull RH, Levick JR, Mortimer PS. Skin microvascular architecture and perfusion studied in human postmastectomy oedema by intravital video-capillaroscopy. Int J Microcirc Clin Exp. 1994 Nov-Dec;14(6):327-34.</citation>
    <PMID>7543461</PMID>
  </reference>
  <reference>
    <citation>Mellor RH, Bush NL, Stanton AW, Bamber JC, Levick JR, Mortimer PS. Dual-frequency ultrasound examination of skin and subcutis thickness in breast cancer-related lymphedema. Breast J. 2004 Nov-Dec;10(6):496-503.</citation>
    <PMID>15569205</PMID>
  </reference>
  <reference>
    <citation>Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, van de Water L. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med. 1992 Nov 1;176(5):1375-9.</citation>
    <PMID>1402682</PMID>
  </reference>
  <reference>
    <citation>Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995 May;146(5):1029-39. Review.</citation>
    <PMID>7538264</PMID>
  </reference>
  <reference>
    <citation>Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002 Nov 1;20(21):4368-80. Review.</citation>
    <PMID>12409337</PMID>
  </reference>
  <reference>
    <citation>Yoshiji H, Kuriyama S, Hicklin DJ, Huber J, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology. 2001 Apr;33(4):841-7.</citation>
    <PMID>11283848</PMID>
  </reference>
  <reference>
    <citation>Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14765-70.</citation>
    <PMID>8962129</PMID>
  </reference>
  <reference>
    <citation>Infanger M, Schmidt O, Kossmehl P, Grad S, Ertel W, Grimm D. Vascular endothelial growth factor serum level is strongly enhanced after burn injury and correlated with local and general tissue edema. Burns. 2004 Jun;30(4):305-11.</citation>
    <PMID>15145186</PMID>
  </reference>
  <reference>
    <citation>Goto T, Fujigaki Y, Sun DF, Yamamoto T, Hishida A. Plasma protein extravasation and vascular endothelial growth factor expression with endothelial nitric oxide synthase induction in gentamicin-induced acute renal failure in rats. Virchows Arch. 2004 Apr;444(4):362-74. Epub 2004 Feb 24.</citation>
    <PMID>14986132</PMID>
  </reference>
  <reference>
    <citation>Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, Lawitts JA, Benjamin L, Tan X, Manseau EJ, Dvorak AM, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med. 2002 Dec 2;196(11):1497-506.</citation>
    <PMID>12461084</PMID>
  </reference>
  <reference>
    <citation>Kasseroller RG. The Vodder School: the Vodder method. Cancer. 1998 Dec 15;83(12 Suppl American):2840-2. Review.</citation>
    <PMID>9874409</PMID>
  </reference>
  <reference>
    <citation>Leduc O, Leduc A, Bourgeois P, Belgrado JP. The physical treatment of upper limb edema. Cancer. 1998 Dec 15;83(12 Suppl American):2835-9.</citation>
    <PMID>9874408</PMID>
  </reference>
  <reference>
    <citation>Casley-Smith JR, Boris M, Weindorf S, Lasinski B. Treatment for lymphedema of the arm--the Casley-Smith method: a noninvasive method produces continued reduction. Cancer. 1998 Dec 15;83(12 Suppl American):2843-60. Review.</citation>
    <PMID>9874410</PMID>
  </reference>
  <reference>
    <citation>Johansson K, Lie E, Ekdahl C, Lindfeldt J. A randomized study comparing manual lymph drainage with sequential pneumatic compression for treatment of postoperative arm lymphedema. Lymphology. 1998 Jun;31(2):56-64.</citation>
    <PMID>9664269</PMID>
  </reference>
  <reference>
    <citation>Loprinzi CL, Kugler JW, Sloan JA, Rooke TW, Quella SK, Novotny P, Mowat RB, Michalak JC, Stella PJ, Levitt R, Tschetter LK, Windschitl H. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. N Engl J Med. 1999 Feb 4;340(5):346-50.</citation>
    <PMID>9929524</PMID>
  </reference>
  <reference>
    <citation>Ueda Y, Yamagishi T, Samata K, Ikeya H, Hirayama N, Okazaki T, Nishihara S, Arai K, Yamaguchi S, Shibuya M, Nakaike S, Tanaka M. A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth. Cancer Chemother Pharmacol. 2004 Jul;54(1):16-24. Epub 2004 Apr 3.</citation>
    <PMID>15064856</PMID>
  </reference>
  <reference>
    <citation>Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer. 2003 Nov 17;89(10):1889-95.</citation>
    <PMID>14612898</PMID>
  </reference>
  <reference>
    <citation>Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marmé D, Steward WP. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol. 2003 Nov 1;21(21):3955-64. Epub 2003 Sep 29.</citation>
    <PMID>14517187</PMID>
  </reference>
  <reference>
    <citation>Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995 Dec 28;333(26):1757-63. Review.</citation>
    <PMID>7491141</PMID>
  </reference>
  <reference>
    <citation>Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991 Jan 3;324(1):1-8.</citation>
    <PMID>1701519</PMID>
  </reference>
  <reference>
    <citation>Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997 Feb;18(1):4-25. Review.</citation>
    <PMID>9034784</PMID>
  </reference>
  <reference>
    <citation>Borgström P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 1996 Sep 1;56(17):4032-9.</citation>
    <PMID>8752175</PMID>
  </reference>
  <reference>
    <citation>Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol. 2002 Nov;161(5):1917-24.</citation>
    <PMID>12414537</PMID>
  </reference>
  <reference>
    <citation>Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997 Oct 15;57(20):4593-9.</citation>
    <PMID>9377574</PMID>
  </reference>
  <reference>
    <citation>Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42.</citation>
    <PMID>15175435</PMID>
  </reference>
  <reference>
    <citation>Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003 Jul 31;349(5):427-34.</citation>
    <PMID>12890841</PMID>
  </reference>
  <reference>
    <citation>Ostendorf T, Kunter U, Eitner F, Loos A, Regele H, Kerjaschki D, Henninger DD, Janjic N, Floege J. VEGF(165) mediates glomerular endothelial repair. J Clin Invest. 1999 Oct;104(7):913-23.</citation>
    <PMID>10510332</PMID>
  </reference>
  <reference>
    <citation>Shen BQ, Lee DY, Gerber HP, Keyt BA, Ferrara N, Zioncheck TF. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem. 1998 Nov 6;273(45):29979-85.</citation>
    <PMID>9792718</PMID>
  </reference>
  <reference>
    <citation>Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol. 1999;237:97-132. Review.</citation>
    <PMID>9893348</PMID>
  </reference>
  <reference>
    <citation>Dvorak AM, Kohn S, Morgan ES, Fox P, Nagy JA, Dvorak HF. The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J Leukoc Biol. 1996 Jan;59(1):100-15.</citation>
    <PMID>8558058</PMID>
  </reference>
  <reference>
    <citation>Feng D, Nagy JA, Pyne K, Hammel I, Dvorak HF, Dvorak AM. Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation. 1999 Mar;6(1):23-44. Review.</citation>
    <PMID>10100187</PMID>
  </reference>
  <reference>
    <citation>Feng D, Nagy JA, Hipp J, Pyne K, Dvorak HF, Dvorak AM. Reinterpretation of endothelial cell gaps induced by vasoactive mediators in guinea-pig, mouse and rat: many are transcellular pores. J Physiol. 1997 Nov 1;504 ( Pt 3):747-61.</citation>
    <PMID>9401980</PMID>
  </reference>
  <reference>
    <citation>Tulpule A, Scadden DT, Espina BM, Cabriales S, Howard W, Shea K, Gill PS. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000 Feb;18(4):716-23.</citation>
    <PMID>10673512</PMID>
  </reference>
  <reference>
    <citation>Granato AM, Nanni O, Falcini F, Folli S, Mosconi G, De Paola F, Medri L, Amadori D, Volpi A. Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools? Breast Cancer Res. 2004;6(1):R38-45. Epub 2003 Nov 25.</citation>
    <PMID>14680499</PMID>
  </reference>
  <reference>
    <citation>Hoar FJ, Lip GY, Belgore F, Stonelake PS. Circulating levels of VEGF-A, VEGF-D and soluble VEGF-A receptor (sFIt-1) in human breast cancer. Int J Biol Markers. 2004 Jul-Sep;19(3):229-35.</citation>
    <PMID>15503825</PMID>
  </reference>
  <reference>
    <citation>Malamitsi-Puchner A, Tziotis J, Tsonou A, Protonotariou E, Sarandakou A, Creatsas G. Changes in serum levels of vascular endothelial growth factor in males and females throughout life. J Soc Gynecol Investig. 2000 Sep-Oct;7(5):309-12.</citation>
    <PMID>11035284</PMID>
  </reference>
  <verification_date>April 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2006</study_first_submitted>
  <study_first_submitted_qc>April 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2006</study_first_posted>
  <last_update_submitted>May 9, 2006</last_update_submitted>
  <last_update_submitted_qc>May 9, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2006</last_update_posted>
  <keyword>breast cancer</keyword>
  <keyword>lymphedema</keyword>
  <keyword>extremity</keyword>
  <keyword>women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

